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Abstract
mHealth apps for patient use are promising but continue to face a plateau in 
usage. Current apps work for a limited segment of the patient population, i.e., 
those who enjoy tracking for intrinsic rewards. There are many opportunities to 
support patient care in between health care provider visits that are not currently 
being met for many diseases and patient types (personas). This is an area of great 
potential growth for mHealth apps and could contribute greatly to patient health 
and wellness. In this chapter, we propose a framework for how to think about the 
between-visit needs of patients that would motivate continued use of mhealth apps. 
We view the app design process from the following perspectives: 1) disease-specific 
needs, 2) non-disease specific needs, 3) behavioral theoretical aspects of app usage 
and 4) app-intrinsic usage motivators. Myasthenia gravis serves as the use case for 
illustrating these perspectives and how to use them in designing a disease-specific 
mHealth app.
Keywords: mHealth, user experience, design, behavior, motivation
1. Introduction
1.1 mHealth app usage remains low, in spite of increased investment
Venture investments in mobile health app development has grown 10-fold over the 
last 5 years, from approximately $200 million in 2014 [1] to over $2 billion in 2019 [2]. 
Investors are hoping to cash in on the rapidly growing mhealth app market, expected 
to grow at a compound annual growth rate of 21% over the next 5 years to an expected 
US$57 billion [3]. However, usage of mhealth apps continues to be low, especially 
amongst patients with chronic disease who are most likely to benefit from their use 
[4]. While 38% of respondents with no health condition had downloaded 1–5 mhealth 
apps in a recent survey, only 6.6% with hypertension had done the same. Actual usage 
of mhealth apps was even more abysmal, with 21% of respondents with no condition 
using the app 2 or more times per day compared with only 2.7% of patients with 
hypertension, 13% with obesity, 12.3% with diabetes and 12% with depression using 
the app at the same level [4]. mHealth app users are more likely to be younger and 
healthier with only 12% of those 55 and over using a mhealth app compared to 25% 
of those under 55 [5]. Interestingly, 34% of mobile users would increase their use of 
tracking apps if encouraged to do so by their healthcare provider (HCP) [6].
Why is app usage so low despite so much investment in the field?
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1.2 There are no standards for design and development of mhealth apps
There are no standard recommendations or approaches to developing 
mhealth apps [7]. Several researchers and app developers have proposed design 
approaches, including some very generic, non-evidence-based approaches 
[8–10] and some based on highly respected frameworks used in other industries, 
such as the information systems research (ISR) framework [11, 12]. The UK 
government provides a thoughtful checklist of items to consider when develop-
ing an app [13].
The ISR framework recommends three cycles of iteration when designing and 
building an app: Relevance, Rigor and Design. Relevance speaks to what users 
want and need to take care of their specific health issues. Rigor implies a review of 
the literature to identify important information that may not have arisen during 
the Relevance cycle. Finally, Design speaks to user-centered design and usability 
evaluation. The ISR framework provides very minimal guidance around what the 
three cycles mean in a healthcare context. It requires starting every project using 
first principles, i.e., assuming nothing is known and that there are no reusable 
elements.
The UK government’s Guide [13] to good practice for digital and data-driven 
technologies is a thoughtful guide to app development and includes several excel-
lent design considerations for app publishers, including ethical considerations, 
defining a clear value proposition, assessing usability and accessibility, ensuring 
technical, clinical and data safety, regulations that should be followed, ensuring 
interoperability, generating evidence of impact and defining the commercialization 
roadmap.
These recommendations and frameworks are very generic and do not address 
important clinical requirements, the raison d’etre of mhealth app development, 
unless they happen to be identified during the primary research process.
All the frameworks and recommendations lack a key recommendation to 
improve chronic disease care: use of a behavior change theory to help drive app-
related behavior change [14, 15]. They also tend to focus solely on the patient 
end-user and leave out a key enabler (or barrier) to app usage: the healthcare 
provider (HCP) [16]. The frameworks also do not specifically address the key 
barriers to app use [17], such as the need to 1) adapt the language and terminol-
ogy used in the app to the needs of those with lower health literacy and numer-
acy levels. In many cases, patients with lower health literacy and numeracy do 
not end up participating in user engagement sessions. This can easily bias the 
app and leave out an important, vulnerable segment of patients who are known 
to use the healthcare system more often [18] and could benefit from use of the 
app. 2) prevent creating a large response burden on patients, i.e., asking patients 
to enter too much data. 3) Make the data collection and analysis relevant and 
actionable for the patient. 4) Make the app very easy to use so that lack of daily 
use does not cause loss of skill in using the app. 5) Create incentives for using 
the app on a regular basis; e.g., creating opportunities for social approval, cost 
savings, a sense of mastery or lowered anxiety. 6) Make it easy for HCPs to see 
that the app is scientifically valid and that it is benefitting their patients and that 
therefore they should encourage its use by the patient and recommend it to other 
patients. 7) Make it easy for HCPs to visualize the data and provide them with 
valuable information that saves them time during the patient encounter so that 
they have an incentive to recommend the app to their other patients. 8) Make it 
easy for the healthcare provider to incorporate the output of the app into their 
electronic medical record system [17].
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1.3 App evaluation criteria are not design criteria
Many organizations and academics have developed criteria for evaluating apps, 
including the author of this paper [13, 17, 19–21]. However, no matter how com-
prehensive the criteria, they are both aspirational, incomplete and highly generic. 
For example, the very popular and highly cited Mobile Apps Rating Scale (MARS) 
assesses constructs such as engagement, functionality, esthetics, information and 
subjective quality. However, the MARS has nothing to say about disease-specific 
functions, integration with the healthcare system, value for healthcare providers, 
whether the app addresses important barriers to use or even whether the app uses 
behavioral theories to help with behavior change. The authors of the study even 
removed the concept of “evidence-based” because it was not assessed during the 
development of the tool. Interestingly, the authors claim that the MARS can be 
used as “a checklist for the design and development of new high quality health 
apps” [19]. The checklist is indeed useful as a general checklist of usability and user 
experience criteria to keep in mind when building the app but does not provide 
much guidance on how to design to achieve clinical benefits.
1.4 Human factors are necessary, but not sufficient for success
Most app design frameworks recommend using a human factors design 
approach [8–12]. These typically include 1) getting some form of input and motiva-
tions for use (user stories) from actual users and developing profiles of the different 
users who might use the system for a shared understanding of users (personas); 
some models call this the empathize step; 2) collating information from multiple 
sources to identify important user problems, also called the define phase in some 
models; 3) developing low and/or medium fidelity mock-ups and working with end 
users to get feedback on them; also called the ideate phase; 4) develop prototypes of 
the most promising ideas; called the prototype phase; 5) conducting expert usabil-
ity, cognitive walkthroughs and end-user testing of the prototypes; called the test 
phase [22, 23].
Not surprisingly, most mhealth app developers do use human factors methods 
in their design process [24]. Despite using these methods, usage of mhealth apps 
continues to be low [4]. This is likely because human factors is only one important 
ingredient in a complex mix of important ingredients [17].
The International Standards Organization (ISO) has recommended a move away 
from user-centred design to a more human-centred design approach [25]. The name 
change is intended to help developers expand their focus from a single user and to 
start thinking more holistically about who the stakeholders of a product really are. 
The ISO recommends six components for human-centred design process, includ-
ing: 1) documenting the needs of users and their relationships to tasks and the 
contexts in which they occur; 2) obtaining user involvement in all stages of design 
and software development; 3) obtaining on-going user feedback and conducting 
on-going evaluation; 4) using an iterative process for product refinement; 5) having 
multidisciplinary skills and diverse perspectives on the design team; and 6) ensuring 
the design encompasses the entire user experience (UX).
1.5 What is the role of personas in app development?
Personas have been an important part of app design for several years [26]. 
They enable product managers and designers to convey important information 
about the end-users to the development team. Personas provide product managers 
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a structured approach to convey basic information about the different types of 
end-users that may use the product. What are the demographics of different users, 
including age, gender, geography? What are their goals, their spending habits, their 
needs, their pain points? What is their orientation to technology (avid, phobic or in 
between)? What is their attitude to the healthcare system (trusting, mistrusting, in 
between)? What is their relationship to their healthcare provider (want to be told 
what to do, want to make decisions themselves)? The persona is usually built after 
conducting research with users and then synthesizing a ‘typical profile’ of either a 
single ideal user or a few different types of users [27, 28].
Personas are particularly important in marketing, as they are typically built on 
well-researched market segments where the desired outcome (purchasing behavior) 
is well known [29]. Personas are essentially a mechanism to make an abstract seg-
ment more concrete for marketers, copy editors and advertising creatives. Personas 
have been adapted for app development, but they lack one important piece of 
information that is available to marketers, but not available to app developers: desired 
user behaviors.
Increasingly, personas are considered as caricatures and not enough for app 
development [30]. They are being augmented by a more powerful model popular-
ized by Clayton Christenson: The Jobs to be Done [JTBD] framework [31, 32]. The 
JTBD framework posits that users do not purchase or use products for the product’s 
sake, but rather purchase them to ‘get a job done’. They ‘hire’ products to accomplish 
a task they need to complete and are looking for an outcome, rather than a feature 
or a function. The JTBD framework is an outcomes specification approach rather 
than a functional specification approach [33].
This framework provides better insight for developing functionality, because 
it immediately goes to the heart of why a user might want to use a product and 
generates a list of ‘jobs to be done’. In the healthcare sector, some of the job to be 
done includes being able to communicate information to the HCP which the HCP 
considers to be relevant and easy to interpret, which is not always clear from a 
end-user persona perspective [34, 35].
The JTBD framework also provides guidance on identifying drivers and barriers, 
both rational/cognitive and affective, for using a product to get the job done [33]. 
This assists developers and product managers to consider unspoken barriers which 
inhibit the use of the product, even when the product is designed to get the ‘job 
done’. It also assists in articulating unidentified drivers that could enhance uptake 
of the product but were not articulated by the end user during user-centered design 
sessions [33].
1.6  Apps need to follow and adapt to evidence-based guidelines for treatment 
and outcomes
One key reason why apps are not used is because the app makes recommenda-
tions which conflict with what HCPs communicate or believe [17]. This creates 
a tension for the patient: “Should I believe the app or should I believe my HCP?” 
Inevitably, unless the patient can find a HCP who agrees with the app, the patient 
realizes the app is not going to be useful, because their HCP is acting on a different 
set of information and therefore embarks on a different diagnostic and treatment 
plan than what the app recommends, rendering the app useless [36].
To make it easier for HCPs to recommend an app to patients, the HCP needs 
to know that the app is scientifically accurate and follows current guidelines and 
regulations [37]. Ideally, the app should be proven to deliver the benefits that 
patients desire and HCPs want to provide, however, this may be a much bigger ask 
than is currently possible. Our ability to evaluate apps as fast as they can change is 
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woefully inadequate [38]. Current approaches used to evaluate drugs do not work 
for evaluating mhealth apps because, while drug formulations stay relatively static, 
mhealth apps are constantly changing.
1.7 Health behavior change is a critical component of mhealth apps
The purpose of providing patients with an mhealth app should be to improve 
their experiences of health care and their health outcomes [39]. If health behaviors 
are optimal, then adding a mhealth app may bring no additional benefit, especially 
if the disease has a lifestyle or behavioral component. Patients with chronic diseases 
which progress over time may also benefit by identifying trends earlier. mHealth 
apps do not have any intrinsic health properties. They, by themselves, do not lower 
blood pressure, treat pain or solve clinical problems. They add their value by help-
ing patients track their relevant clinical problems, visualize their current behaviors, 
experiment with new behaviors and see the impact of their new behaviors on 
their health, including medication taking behaviors. Thus, the current short-fall 
in health-related behaviors (whether lifestyle or medication-related) that leads to 
poor health experience needs to be identified and the app needs to directly address 
the highest priority short-falls and those at highest risk for exhibiting poor health 
behaviors. It is likely that if the app is successful in addressing healthcare needs of 
the individual and their HCP, then the health of the user will improve, and they will 
no longer need the app. To maintain on-going and continuous use, app developers 
will need to continuously evaluate the impact of their app on patient health and add 
new functions to the mhealth app in future iterations.
If the app does not respond to evolving clinical needs, changes in therapy, 
changes in knowledge about behavior change techniques that work or changes in 
guidelines, the app is likely to become obsolete and lose users who increasingly 
experience barriers to the use of the app from their HCPs [36]. mHealth app devel-
opment is a dynamic industry.
In addition to relevance and timeliness, mhealth apps need also to be built on a 
well-researched behavior theory. There are as many as 89 different behavior theory 
models that have been developed over the last several decades [15], too many to 
list here. However, having a theory of behavior change to underpin app features 
is important for several reasons: 1) you cannot change what you do not know; it’s 
important to know current behaviors so they can be measured and tracked through 
the change process. 2) Understanding the mediators of behavior change allows 
developers to tease out whether a lack of response was due to poor design of the 
intervention or whether the intervention worked properly but had no impact on the 
relevant behavior. 3) Theories of behavior build upon a large body of knowledge 
and are more likely to work than a poorly informed and poorly conceptualized 
intervention.
Carey et al. provide a website where app developers and change agents can find 
links between behavior change theories and mechanisms of action [40]. Although 
this is an excellent service, using behavior change theories that have already been 
proven for a particular disease may be a much better approach than trying to pick 
theories based on conjecture or putative mechanisms of action [41, 42].
1.7.1 Literature review and research trump end-user engagement
Every disease is different, and every patient experiences their disease in a unique 
way. For example, type II diabetes is caused by a myriad of social, environmental 
and physiological factors related to physical activity and nutrition. In contrast, 
our case study disease, myasthenia gravis is an autoimmune disease that can be 
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triggered or worsened by social, environmental and physiological factors, but is 
not caused by them. These differences have profound influences on what the most 
effective mhealth interventions are likely to be [43–48].
It is important to understand the range of behaviors that are detrimental for 
someone with a particular disease. Poor nutritional and exercise habits are impor-
tant barriers for good health in diabetes [49], while poor medication adherence and 
exposure to exacerbating conditions are important considerations in myasthenia 
gravis, for example [50]. This type of information may be available from end-users 
during end-user engagement sessions, but typically requires systematic investi-
gation by researchers and experts rather than by app developers who may miss 
important information because they lack expertise in a particular clinical topic [15]. 
Literature review and synthesis is a key requirement of mhealth app development.
1.7.2  Ability to change health behaviors requires an understanding of the range of 
ways that patients experience their disease
For a mhealth app to be effective, it needs to not only provide evidence-based 
advice, but also needs to capture and track relevant disease-specific patient 
behaviors. In diabetes, this is likely to be nutrition, exercise, stress, medication 
adherence, regular monitoring of biomarkers and sleep. In myasthenia gravis, it 
will include medication adherence, exposure to exacerbating factors, stress and 
potentially muscle strength.
Regardless of the relevant disease-specific behaviors, different patients with the 
same disease have different preferences and beliefs which also impact their choice of 
treatments, their health behaviors and approach to interacting with the healthcare 
system [51]. These differences in patient experience need to be considered during 
the app design and development process. These differences can be captured as part 
of the persona development process.
1.8 App-related behavior change is not health behavior change
How users relate to apps is very different from the way they relate to their 
disease. Health-related behaviors are highly dependent on the nature of the disease, 
while app related behaviors are dependent on characteristics of the app and the 
clinical setting; i.e., ease of use, user experience, getting the job done and a sense of 
accountability to the HCP and the healthcare team.
A significant majority of mhealth apps do not use a theoretical basis for 
driving behavior change [52]. Geuens et al. [53] describe a tool which links 
behavior change theories to mhealth app features to make it easer for developers 
to incorporate behavior change theories into their applications [54]. The features 
in the Trustworthiness and Liking section are all related to better app use. An 
excellent and comprehensive list of methods to improve app usability mentions 
many good techniques to improve app usability and the user experience, includ-
ing 1) minimizing cognitive load, 2) minimizing response burden, 3) breaking 
down tasks into smaller sub-tasks, 4) making it easy to navigate and know where 
you are in the app, etc. [55].
1.9  Not all patients are alike. Patient segmentation is necessary for personalizing 
care
Not all patient segmentation approaches are relevant to mhealth app design. 
For example, the approach recommended by Brommels [56] which breaks down 
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patients into 7 categories (healthy, incidental, chronic disease, multi-morbid, 
needing elective treatment, trauma, requiring hospitalization) is more suited to 
health delivery systems and how to segment patients for health delivery planning. 
The approach used by Deloitte who categorize health consumers into 4 categories 
(trailblazers, prospectors, bystanders and homesteaders) is more suited to under-
standing patients as consumers and purchasers of healthcare as opposed to as 
individuals who are purchasing a product to solve a problem [57].
What app developers need is a method to segment patients to enable more 
personalized solutions and communications for patients [51]. A Finnish organiza-
tion has developed such a segmentation approach for Diabetes [58] and Sandy 
et al. developed one for hypertension [59]. Ideally, app developers should find a 
well-researched patient segmentation approach for the disease for which they are 
building an app.
1.10  Ecological momentary assessments and interventions are useful theoretical 
constructs
There’s a lot of hype about using sensors embedded in smartphones to detect 
changes in usage patterns which imply a worsening of disease [60] or for detection 
of disease [61–63]. Even very recent studies are exploratory and need additional 
validation before being translated into the field [64, 65]. Although the research 
base that makes production use of smartphone sensors is still in its infancy [66], 
there are some promising developments in creating architectures that are ready for 
conducting research. Digital (behavior) phenotyping, the ability to use wearables 
and sensor data to detect different behaviors, is developing rapidly and it is likely 
that the basic science will become more easily accessible over the next several years 
[67]. The developers of the geographically explicit ecological momentary assess-
ment (GEMA) architecture claim that their approach is scalable from their study in 
post-partum mothers to other disease areas [68].
The use of validated patient reported measures questionnaires for conduct-
ing ecological momentary assessments is well developed and can be used with 
good design in terms of frequency and response burden [69, 70]. Patient reported 
experience and outcomes measures (PREMS and PROMS) have been developed in 
a variety of disease areas and are a promising way for mhealth app developers to 
get a jump start on ecological momentary assessments [71–74]. Use of PREMS and 
PROMS may incur a license fee but are worth the cost since the tools are generally 
validated and are widely used in clinical trials. Care must be taken to select PREMS 
and PROMs properly, since some of them are more useful as aggregate measures 
(suitable for clinical trials) but are not appropriate for use on individual patients in 
a clinical setting [75].
Ecological momentary interventions are another promising concept, especially 
in the mental health field, where cognitive and affective interventions can be 
delivered directly through an app [76–78]. Although it is possible for apps to be used 
for other interventions, such as driving insulin pumps in response to readings from 
a continuous glucose monitoring system [79] this is still unusual and very much in 
its infancy.
Ecological momentary interventions are also very promising for delivering 
behavior change interventions at just the right time [80]. Ideally, delivery of 
interventions should be timed to when people are most receptive to receiving them. 
Timing of interventions can be predicted by use of ecological momentary assess-
ments to know when a patient might be at their worst or at their best and deliver an 
intervention at just the right time [81, 82].
Smart and Pervasive Healthcare
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1.11  Effectiveness assessment requires a rapid research infrastructure and new 
research methodologies
Many app guidelines request app developers to test their app for clinical benefits 
[13, 83]. However, testing apps can be a fraught process, because typically, apps 
are designed and developed using an agile process, but clinical evaluation requires 
a more waterfall process. The methodologies for development and evaluation are 
somewhat incompatible and creates friction for good quality clinical trials. Philpott 
et al. make some recommendations about how to create a clinical trials infra-
structure that is more flexible to the needs of mobile health app evaluation. They 
recommend a 2-phase approach. The first phase is a qualitative phase with usability 
and expert reviews to ensure that the app meets minimum criteria for more rigor-
ous testing. The second phase then evaluates the app in an adaptive randomized 
controlled trial, which allows low quality apps to be identified and quickly removed 
from the study and allows high quality apps to be tested more rigorously [38]. This 
ensures that scarce resources are not wasted on apps that do not add value.
2. Use case: myasthenia gravis
Myasthenia gravis (MG) is a chronic autoimmune disease that targets the 
neuromuscular junction and causes unpredictable, fluctuating muscle weakness. 
Symptoms include drooping eyelids (the classical, textbook symptom), difficulty 
breathing, upper and lower limb weakness, difficulty swallowing and slurred 
speech [84]. MG affects about 20 people in every 100,000 [85]. It is twice more 
prevalent in women who get it in their 20s–30s than in men who get it in their 
60s–80s. At one time, the mortality rate for MG was as high as 75%. However, with 
advances in treatment, the mortality rate is down to less than 5% [85]. Patients with 
MG are treated by neurologists.
We use myasthenia gravis as the use case for demonstrating a framework for 
designing the clinical aspects of a mobile health app.
2.1 Identifying and designing for disease-specific needs
Patient focus groups were formed before any app development activities were 
started to get patient input on whether an app would add value and if so, what 
the app should encompass. Patients agreed that an app could fill a gap that exists 
in care. They provided information about their experience of their disease and 
provided high level guidance about the features, functionality and benefits they 
would like to see in an app.
Clinician (neurologist) key informant interviews (N=8) were held to gather clini-
cian experiences and gather clinician input into what they would like to see in an app 
for MG. Clinicians indicated that they struggle with capturing important informa-
tion about the patient’s disease progression, medication use and compliance and the 
broad range of quality-of-life issues that patients with MG face. Clinicians are also 
interested in learning more about objective physical signs and not just the subjective 
patient experience. Key clinician-anticipated benefits from an app include getting a 
better, more detailed timeline of key events without the fog of recall bias and getting 
a better sense of medication compliance. There was no consensus on how to track 
patients between visits, but everyone knew about the MG Activities of Daily Living 
questionnaire (MG-ADL) [86]. Clinicians indicated that an app would also benefit 
primary care physicians, who are taking on more of the care of patients with MG.
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Key neurology opinion leaders (N=7) were also interviewed to better understand 
the context in which the app would be introduced, what metrics the app would need 
to exhibit for them to support it and reasons they would need to recommend it to 
other clinicians.
2.1.1 Experiences of patients with MG
Patients with MG have unique disease-specific experiences. They experience 
anxiety (from the uncertainty of their disease) and social negativity (forced 
withdrawal from normal social activities). They experience stigma, deconditioning 
and exhaustion. Many experience stigmatizing side-effects of the medication, such 
as obesity, skin rashes and poor mood. Many experience disability and are unable 
to work.
There are 3 possible reasons that patients experience worsening of symptoms: 
1) a worsening of the underlying disease process leading to worsening of symp-
toms, 2) poor compliance to medication and 3) patient is experiencing exacerbat-
ing factors, such as stress, lack of sleep, extreme heat or cold, contraindicated 
medications and viral illness.
Although one benefit of using an app could be that patients receive an escalation 
in treatment sooner, many patients paradoxically fear dose escalation because of the 
side effects they experience from using some medications. It is hoped that better 
tracking of exacerbating factors could help minimize dose escalations by identify-
ing triggers for worsening of symptoms, other than a worsening of disease. All these 
assertions would, of course, need to be tested.
We combined disease-specific factors and patient motivations to create 4 
personas: 1) The In-Charge is a user with intrinsic motivation to use the app 
because they like to collect data and analyze it for insights that they can act upon 
themselves. 2) The Worrier is anxious about the disease, the symptoms they 
experience, how the medication makes them feel, how they will cope if things get 
worse and the uncertainty of when the next exacerbation will occur. They also 
worry about how others perceive them and the loss of control they have over their 
lives because of MG. 3) The Adaptive Manager seeks to control events by gathering 
as much information as possible and partnering with their doctor to be proactive 
and manage their disease in the best way possible. And 4) the Passive Monitor 
who collects information because their doctor has asked them to do so. They trust 
that if their doctor thinks it is a good thing, then it must be so. There is of course a 
fifth persona: The Non-User. The Non-User does not believe that an app can be of 
enough benefit to make it worth their while to use.
2.1.2 App design considerations
The key underlying premise for developing the MG mhealth app was to help 
patients track their symptoms, treatments and exacerbating factors in between 
visits to their doctor so that they can self-manage their disease better and so that 
their HCP can review information in the app to get a more accurate and more 
comprehensive summary of what happened since their last visit. We selected the 
validated MG quality of life tool called the Myasthenia Gravis Activities of Daily 
Living profile (MG-ADL) [86] to capture data about patient symptoms. The app 
also allows tracking of some common physical activities such as walking the dog 
or climbing stairs which are important to the patient. This provides them with the 
ability to track how well they are doing for important activities which may not be 
considered to be ‘activities of daily living’.
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Benefits and goals of tracking symptoms, medication use, health system use 
and exacerbating factors we identified included, 1) patients may identify reasons 
for disease worsening earlier with use of the app and, in some cases, be able to 
act on the information themselves; e.g., get more sleep or avoid situations which 
make their disease worse (benefit to In-Charge and Adaptive Manager). 2) Patients 
may make the visit with their HCP more efficient and productive, giving them 
more time to ask questions that are important to them (benefits Worrier, Adaptive 
Manager). 3) Patients may receive treatment escalation sooner, if the HCP is better 
able to tease out worsening of underlying disease from a string of bad days (benefits 
all patient types). These benefits are communicated to the patient throughout the 
app, to remind them of the benefits and reinforce use of the app.
Most patients (75% of women and 56% of men) do not like the side-effects of 
prednisone and resist dose escalations [87]. Making it easy for patients to capture 
more granular information about their medication use may be helpful for physicians 
to tailor doses and minimize the dose escalations or minimize the duration of a dose 
escalation. Rather than asking patients to enter all their medication data into the 
app and track detailed usage, it may be as valuable to capture the main 2 most prob-
lematic medications used in the treatment of MG and ask the patient periodically 
whether they used it as prescribed and if not, why not. That information would be 
easier for the patient to enter and may be just as helpful to the HCP as a much more 
detailed log of medication use.
Fear, uncertainty, change and stigma are a big part of the MG experience [88]. 
Using more reassuring and calming language, without promising anything that 
cannot be delivered by the app is a good way of addressing anxiety. A root cause 
of stigma is ignorance. Providing useful facts about MG to the patient about 
self-management and how to explain their disease to others could help decrease 
uncertainty and stigma and help the patient cope better with unavoidable change. 
These facts and messages can be entered into a fact and message bank that can 
be displayed to the patient randomly, helping to keep the app fresh and educat-
ing patients at the same time. In future iterations, the app may wish to include 
an optional cognitive behavioral therapy component and/or a mood or anxiety 
tracker.
Patients who desire more control over the app (In-Charge and Adaptive 
Manager) are given an opportunity to make changes to the settings for a variety 
of features. Expert review identified that some of the features that patients could 
control (for example, what would be released to their HCP in the report) would 
only increase their anxiety and have a paradoxical effect on patients perceived 
control over the app. It was recommended that the control over the HCP report be 
removed as it did not impact the patient. The reports provided to patients were also 
harmonized to look more like what was provided to the physician so that they would 
not be disoriented when having a conversation with their HCP.
Patients with MG frequently experience exhaustion, which is independent 
of muscle weakness, the hallmark of the disease. This means that patients with 
MG spend a lot of time in bed, unable to move, but still able to think and perform 
cognitive tasks. We recommended that the app provide a function to lock the aspect 
ratio so that patients can view the app in the more convenient portrait mode while 
lying down.
Almost half of patients with MG experience reduced social positivity and 
physical activity, increasing their chances of becoming depressed and becom-
ing deconditioned. Future iterations of the app will consider adding a gratitude 
journal and/or a cognitive behavioral therapy component. Future iterations could 
also provide the patient with a physical activity program to prevent physical 
deconditioning.
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2.2 Identifying and designing for non-disease-specific drivers and barriers
Patients experience many frictions to use of apps [17]. A small segment of 
approximately 20% of the app-using population has an intrinsic motivation to use 
an app [89]. They track their disease on a regular basis from an internal motivation 
with little encouragement – they will use an app if you offer them one. Another 34% 
of users say they would use an app if their doctor recommended it [6]. Making the 
app useful to HCP will make it more likely that HCP will endorse and encourage 
use. We addressed the following issues in our design.
2.2.1 App provides information that conflicts with information received from HCP
We designed the app to be consistent with current guidelines or current stan-
dards of practice in MG. Unfortunately, the current MG treatment guidelines 
are not well-respected and utilized. In this case, we asked our clinical advisors to 
provide us with the latest information about diagnosis, treatment and management 
of patients with MG. The clinical advisors provided guidance to include simple 
medication and health system outcome tracking which is important to doctors. It 
will be important to ensure that app maintenance includes regular check-ins with 
neurologists to update the app to current standards of practice.
2.2.2  Language and terminology of the app not compatible with the patient’s 
health literacy
We simplified the language used in the app. Although it is very difficult to 
translate all medical issues to a grade 6 level, where possible, we minimized use of 
difficult words and used the same difficult terminology in different contexts so 
that users would learn their meanings after repeated use. We repeated important 
concepts to reinforce learning. We used language that was compatible with the 4 
different personas we identified (see below). We also reframed messages on goals 
and outcomes to appeal to the various types of users.
2.2.3 Patient must enter the data himself or herself
We minimized data entry tasks and burden (aka response burden) by asking 
patients to identify what was important to them. Although the questionnaire is 
relatively short at only 8-questions, not all questions are relevant to all patients. In 
a clinical trial setting, there is no option but to use the entire scale because missing 
data can easily invalidate a study. However, for an app that tracks the individual 
effectiveness of clinical treatment, focusing on what’s most important to the patient 
can go a long way to decreasing response burden and increasing compliance to data 
capture; some data is always better than no data. The purpose of the app is not to 
capture data, but to help the patient manage their disease and to track the trajectory 
of their disease. If the patient rarely or never experiences a particular symptom, 
there is no need to track that information. If patients experience their worst 
symptoms in a particular part of their body, then tracking that symptom may be an 
excellent sentinel event for tracking overall disease state. Using this approach, we 
were able to decrease the number of questions that the patient had to answer.
Another way to reduce response burden is to ask patients to fill out the question-
naire randomly spread out over a longer period. By ‘sampling’ the patient’s disease 
experience over a longer period, it is possible to get a good sense of the patient’s 
disease trajectory and then sample more or less frequently to optimize the amount 
of information compared to the response burden for the patient.
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The magnitude and/or the magnitude of change in patient responses can also be 
used to make data entry more meaningful to the patient. If the patient’s symptoms 
are low and/or stable, the app can take longer to notify the patient to enter data. If 
the patient’s symptoms are worse or changing, then capturing data more frequently 
makes more sense and is likely to be more acceptable to the patient.
2.2.4 Patient cannot use information in a meaningful way
Patients generally have little control over their clinical condition. They cannot 
order diagnostic testing, prescribe medications or refer themselves to specialists. 
They are dependent to a great extent on their HCPs for those clinical actions. 
However, it does not mean that they have no control over their condition.
In myasthenia gravis, the patient has 1 major concern on a day-to-day basis: 
when my symptoms worsen on any one day, am I just having a ‘bad day’ or is it a 
worsening of my underlying condition? The uncertainty of symptom worsening can 
be a great source of anxiety [88]. The app could help patients see the trends of their 
disease and help them better and more quickly distinguish between a ‘bad day’ and 
a worsening of their disease, thereby giving them greater control over their disease 
experience.
The other way that patients can be empowered to use the app is to provide an 
easy-to-use report from the app for their HCP. This report, if useful and used by the 
HCP, would benefit the patient directly. Because of the uncertainty and daily varia-
tion in symptoms experienced by patients with MG, recalling their symptoms and 
experience of their disease during a visit with their HCP can be challenging. This 
was confirmed by our panel of clinical experts who indicated that history taking in 
MG is challenging and time-consuming. HCPs are likely to benefit from and value a 
simple, easy to read, visual report of the patient’s symptoms overlaid with informa-
tion about compliance to medication and exacerbating factors experienced at the 
time of symptom worsening. Since, this is the most beneficial information for HCP, 
we need only capture medication compliance and exacerbating factor information 
at the time of symptom worsening, thereby minimizing response burden further.
Patients are influenced by non-verbal cues from their HCP. If the HCP does not 
use the information in the report, they are likely to stop using the app. However, 
if patients perceive that HCPs value the reports, they will continue using the app. 
HCPs have a strong influence on patient app usage and can reinforce app usage by 
requesting the report and by viewing the information and acting on in it, where 
appropriate.
2.2.5 Lack of incentives like cost saving or social approval
There are few external incentives for using an app in MG. MG is not a lifestyle 
disease, so getting empathy from other people is rather difficult. MG is also a stig-
matizing disease (see below), so social sharing of progress may not be appropriate 
or desired by the patient. However, there is a useful behavior change theory called 
the Self-determination Theory (SDT) [90] which was determined to be appropriate 
for patients with MG and could provide a significant incentive to use the app. How 
SDT was incorporated into the app is described below in Section 2.3.
2.2.6  Daily use of the app is not required and therefore patient does not get into the 
habit of using it
Although patients with MG can experience symptoms at any time, the lived 
reality is that exacerbations and improvements play out over weeks and months. 
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Collecting data everyday can become tedious and lead to response fatigue. How do 
we design an app that maintains a good balance between infrequent data collection 
and loss of skill over time?
Through Expert Usability reviews, we simplified the data collection so that 
patients only reported data about the symptoms that are most troublesome to them. 
We also simplified the task loops so that they could get feedback from their data entry 
in smaller cycles of data entry, instead of getting one big report after answering a long 
series of questions. Encouraging and educational messages are spread throughout the 
data entry tasks so that patients do not get fatigued with answering many questions. 
Messages that explain the rationale for capturing specific information can help the 
patient connect the data they are entering to the outcomes they are hoping to achieve.
Notifications can help remind the patient to track information. To improve response 
rates, the notification could be developed to enable data entry directly into the notifica-
tion rather than having to open the app and enter the data there. This is particularly 
useful where a single response is required, such as ‘Did you take your medications as 
prescribed yesterday?’ It is better to ask a question like that about a completed time unit 
rather than asking it for an incomplete time unit, since there is a finite chance that the 
patient may not have completed a task that the app is asking about.
2.2.7  HCPs may not value or use the data collected by patients in apps whose 
provenance and pedigree is not known or established
It is important that HCPs understand how the app was designed, who was 
involved in the design and what evidence was used to guide its development. More 
importantly, this information will be more credible and trustworthy if they hear 
it from their peers and key opinion leaders they look to for knowledge about new 
products in their field. If HCPs are convinced about the benefits of the app for 
themselves and their patients, based on reports from opinion leaders who have 
already tested the app in their own practices, the more likely it is that they will be 
the ones to recommend it to patients in the first place, obviating this barrier.
2.2.8  There is no way for HCPs to consume the large amounts of data that are 
collected in apps
HCPs do not have time to download data from an app, clean it up, analyze it and 
visualize it during a patient encounter. The entire task needs to be done for them 
before the patient even arrives at the clinic. It should already be in the patient’s 
electronic medical record when the HCP is reviewing the chart. The app should 
generate a simple report that the patient can email to their HCP so it can be attached 
to the record by the time the patient arrives.
The report should summarize the data from the previous 3–6 months since the 
last visit and should provide the HCP with actionable information. Do the exacerba-
tions point to a worsening of disease or just poor control on the part of the patient? 
Is the poor control because of poor compliance to medication or due to exacerbating 
factors? If the HCP can answer these two main questions, they can have a more 
fruitful discussion about the patient’s goals and how they can be achieved, rather 
than spending most of their time sorting out what happened since the last visit.
2.2.9  HCP is unable to integrate app data into their own EMR for analysis or 
follow-up or share the data in their EMR with their patient’s apps
The current state of interoperability in most jurisdictions has not matured to the 
point where this type of digital data exchange can occur easily or quickly. HL7’s Fast 
Smart and Pervasive Healthcare
14
Healthcare Interoperability Resources (FHIR) standard is evolving rapidly and is 
likely to be readily available over the next 5–10 years. As of late 2021, it is relatively 
immature and not ready for production use with apps.
2.3 Identifying and designing for a behavior-theoretical model
Through a process of discussion, reflection and mapping the experience of 
patients with MG to various behavior change theories, we determined the Self-
determination Theory (SDT) [90] to be appropriate for patients with MG. SDT 
posits that people have a need for personal growth and that there are 3 intrinsic 
motivators that drive that growth: 1) A need for mastery over life’s situations 
(Competence); 2) a need to feel in control over our lives (Autonomy); and 3) a need 
to feel connected to others (Relatedness).
SDT has a strong connection to the lived experiences of people with MG. Many 
patients with MG want to have more control over their lives and be able to do that 
through more knowledge and skills about their disease. They also want to gain 
greater connectedness to their HCP to get better guidance on how to manage their 
disease and faster time to treatment. The incentive for using the app should be 
rooted in a behavior theory that is compatible with improvement of the disease 
experience.
We incorporated the 3 elements of the SDT by providing more facts and infor-
mation that the patient can use to manage their disease, by providing visualizations 
of the data they collect to help them see how well they are doing and what they 
can do to improve their disease experience and providing them with a concise and 
easy to understand report suitable for sharing with their HCP, thereby promoting 
control and relatedness at the same time. These factors can be refined over time, as 
patients start interacting with the app in the real-world.
2.4 Identifying and designing for app-related behaviors
App-related behaviors were considered at various stages of app use: 1) dur-
ing on-boarding, 2) when capturing baseline data, 3) during routine use. The 
Elaboration Likelihood Model and the Information-Motivation Behavioral Skills 
model are excellent behavior change models for use in mhealth app design and 
development as the focus on app-related behaviors [54].
The Elaboration Likelihood Model (ELM) states that behavior change will 
usually arise after a change in one’s beliefs and attitudes and that a change in beliefs 
and attitudes can be triggered by a cognitive stimulus, i.e., a message or fact. The 
ELM proposes several mechanisms for delivering the cognitive stimulus, including 
personalization, verifiability, expertise and surface credibility.
The Information-Motivation Behavioral Skills (IMB) model states that new 
behaviors are the result of information, motivation and skill in executing a behavior. 
The IMB proposes the following mechanisms for delivering relevant information, 
motivations and skills to patients: reduction of effort needed to do something, tun-
neling to breakdown large goals into smaller, more manageable goals, reminders that 
help the patient remember to do a task and macro tailoring which means adapting 
messages to the needs of a specific group or segment.
During on-boarding, we want to make it fun and easy for users to start using 
the app. The first few screens do not require any data entry (reduction). They 
inform the patient about the app, explain the benefits of using the app from the 
perspective of all the different personas (macro tailoring) and start educating the 
patient about how to use the app and what to expect from using the app. The app’s 
design is very professional and has a clean and visually appealing look and feel, 
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giving the app surface credibility. The patient also learns that the app has been 
developed by experts in the field (expertise).
When capturing baseline data, the patient is offered some control over what 
they would like to track and share with their HCP (personalization). Although all 
patients are asked to enter the minimum data that will generate a report for the 
HCP, they have the option of only capturing relevant information about their 
symptoms. Once they have entered a small amount of data, they are offered a 
visualization of their information (tunneling). Baseline capture occurs on the first 
day of use. The aim is to keep the session relatively short and pleasant, even though 
the patient is likely to be excited about using the app for the first time and would be 
willing to spend a lot more time with the app. Allowing the patient to get too excited 
could lead to overinflated expectations and disappointment.
Once the patient has entered their baseline information, they enter the routine 
use phase. During this phase, they can explore the app, learn about their disease and 
learn about the provenance of the information made available to them (verifiability). 
They also receive notifications to enter data periodically (reminders) and can change 
the settings to personalize the schedule of notifications.
3. Conclusion
This chapter contributes new knowledge about how to design the clinical com-
ponents of a mobile health app. It does not replace existing guidelines and frame-
works for mobile app development in general and mhealth apps specifically. Rather, 
it complements existing approaches and adds new information that may be helpful 
for app developers when designing the disease-specific features and functions 
of an mHealth app. Specifically, it adds the following to our current knowledge 
about designing mhealth apps: 1) It makes a distinction between disease-specific 
behaviors and needs and non-disease-specific barriers and needs. This enables app 
designers to dig down deeper into specific health-related experiences and encour-
ages them to identify information in the literature which might illuminate app 
development. It provides a list of common barriers to mhealth app use and potential 
solutions to those barriers. 2) It makes a distinction between disease-related behav-
iors and app related behaviors. These are two very different types of behaviors and 
should have different design approaches, including use of different behavior change 
theories to underpin them.
This chapter also brings together several existing concepts and design patterns 
into a more coherent mhealth app design approach. We identify that human factors 
methodology is necessary but not sufficient for app development and recommend 
the expansion of user-centred design to human-centred design that considers 
a wider group of stakeholders, especially the HCP and the opinion leaders who 
influence them. We complement the use of personas with the Jobs to be Done 
framework and explain the key limitation of using personas in the design of apps 
compared to their use in marketing. We elaborate on the use of patient segmenta-
tion using disease-specific criteria, rather than generic or health-system level 
segmentation as a way of meeting the needs of different patient types and different 
app user types.
The limitations of this framework include the fact that the outcomes of using the 
framework have not been tested in the real-world and that there are two issues that 
the framework does not address. These include no research-based or proven guid-
ance on 1) how to make a mhealth app engaging or 2) how to make an app visually 
appealing. In addition, we did not include any guidance on behavioral economic 
theory and choice architecture, also known as ‘nudge theory’ [91].
Smart and Pervasive Healthcare
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